Adam Hendricson
Associate Director of Neuroscience Arvinas, Inc.
Seminars
Wednesday 28th October 2026
The Expanding Frontier of Targeted Protein Degradation: Translational & Clinical Advances in Neurology & Immuno-Oncology
11:45 am
- Clinical biomarker data from LRRK2 program informing target engagement and pharmacology
- Emerging data in polyQ-AR and HPK1 programs highlighting early signs of broader applicability across neurological and immuno-oncology targets
- Foundational overview of PROTAC degrader design and mechanism
